The relationship of circulating MOTS-c level with liver fibrosis and metabolic components in patients with metabolic dysfunction-associated fatty liver disease.

Kirik A, Dogru T, Yanik B, Sen H, Eroglu M, Baykan O, Bozyel EA, Ergene A, Selçuk E, Tasci I, Sonmez A

European review for medical and pharmacological sciences1 Sept 2023Cited by 8 (Europe PMC)

PMID37750635DOI10.26355/eurrev_202309_33567PepBankPUB-37750635

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Natural levels measured6

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In adults with MAFLD, circulating MOTS‑c levels were lower than in healthy controls.
In plain wordsPeople with fatty liver disease had lower levels of the body's own MOTS‑c than healthy controls.
Peptide
MOTS-c
Outcome
DecreaseMOTS-c in MAFLD vs healthy controls
Study
n = 234
Comparator
Healthy controls
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Patients with MAFLD had significantly lower MOTS-c levels than the healthy controls (p=0.009).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a single-center cross-sectional study, and the participants were divided into two groups based on their liver ultrasound results: the fatty liver group and the healthy control group.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3775063501
02HumanEndogenous levelObservational studyOther
Circulating MOTS‑c levels were lower in subjects with metabolic syndrome than in those without.
In plain wordsPeople with metabolic syndrome had lower levels of the body's own MOTS‑c than people without it.
Peptide
MOTS-c
Outcome
DecreaseMOTS-c in subjects with vs without metabolic syndrome
Study
n = 234
Comparator
Subjects without MetS
Outcome group
Mitochondrial function · Metabolic and weight
Source sentences
Summary
The MOTS-c level was significantly lower in subjects with MetS (n=48) compared to those without MetS (n=186) (p=0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a single-center cross-sectional study, and the participants were divided into two groups based on their liver ultrasound results: the fatty liver group and the healthy control group.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3775063502
03HumanEndogenous levelObservational studyOther
In the total study population, MOTS‑c levels correlated negatively with the presence of MAFLD.
In plain wordsLower levels of the body's own MOTS‑c were linked to having fatty liver disease.
Peptide
MOTS-c
Outcome
DecreaseCorrelation of MOTS-c with presence of MAFLD
Study
n = 234
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
In the total population (n=234), MOTS-c levels negatively correlated with the presence of MAFLD, NFS, FIB-4, and components of MetS.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a single-center cross-sectional study, and the participants were divided into two groups based on their liver ultrasound results: the fatty liver group and the healthy control group.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3775063503
04HumanEndogenous levelObservational studyOther
In the total study population, MOTS‑c levels correlated negatively with the NAFLD fibrosis score.
In plain wordsLower levels of the body's own MOTS‑c were linked to higher liver scarring scores.
Peptide
MOTS-c
Outcome
DecreaseCorrelation of MOTS-c with NAFLD fibrosis score
Study
n = 234
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
In the total population (n=234), MOTS-c levels negatively correlated with the presence of MAFLD, NFS, FIB-4, and components of MetS.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a single-center cross-sectional study, and the participants were divided into two groups based on their liver ultrasound results: the fatty liver group and the healthy control group.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3775063504
05HumanEndogenous levelObservational studyOther
In the total study population, MOTS‑c levels correlated negatively with the FIB-4 fibrosis score.
In plain wordsLower levels of the body's own MOTS‑c were linked to higher liver scarring scores on FIB-4.
Peptide
MOTS-c
Outcome
DecreaseCorrelation of MOTS-c with FIB-4
Study
n = 234
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
In the total population (n=234), MOTS-c levels negatively correlated with the presence of MAFLD, NFS, FIB-4, and components of MetS.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a single-center cross-sectional study, and the participants were divided into two groups based on their liver ultrasound results: the fatty liver group and the healthy control group.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3775063505
06HumanEndogenous levelObservational studyOther
In the total study population, MOTS‑c levels correlated negatively with components of metabolic syndrome.
In plain wordsLower levels of the body's own MOTS‑c were linked to more features of metabolic syndrome.
Peptide
MOTS-c
Outcome
DecreaseCorrelation of MOTS-c with metabolic syndrome components
Study
n = 234
Outcome group
Mitochondrial function · Metabolic and weight
Source sentences
Summary
In the total population (n=234), MOTS-c levels negatively correlated with the presence of MAFLD, NFS, FIB-4, and components of MetS.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a single-center cross-sectional study, and the participants were divided into two groups based on their liver ultrasound results: the fatty liver group and the healthy control group.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3775063506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.